



Jean-Christophe Tellier

Chief Executive Officer

Chairman of the Executive Committee

Company statement

UCB (www.ucb.com) is an innovation-driven global biopharmaceutical company focused on the discovery and development of novel medicines and solutions to transform the lives of people living with severe diseases.

Thanks to a truly patient-centric approach and a strategy focused on two therapeutic areas, immunology and neurology, UCB is enjoying a period of sustainable growth, with no major patent expiries within the coming decade. In the last years, the company has brought several innovative drugs to patients across the world: Cimzia[®] (certolizumab pegol) in various arthritis indications and Crohn's disease, Vimpat[®] (lacosamide) and Briviact[®] (brivaracetam) in epilepsy and Neupro[®] (rotigotine) in Parkinson's disease and restless legs syndrome.

With research collaborations with eminent universities and third parties, UCB enjoys a rich pipeline of future promising drugs and has built one of the most productive R&D organizations in the industry.

Jean-Christophe Tellier

Jean-Christophe Tellier joined UCB in 2011. He became UCB's Chief Executive Officer on January 1, 2015 after having successfully led UCB's BioBrands and Solutions division as Executive Vice President.

He is a member of the Board of Directors of UCB, a member of the Board of WELBIO (Walloon Institute for Life Lead Sciences) and of BIO (Biotechnology Industry Organization in the US) and of PhRMA (Pharmaceutical Research and Manufacturers of America). He is also Vice-President as well as a President-Elect of the Board of the European Federation of Pharmaceutical Associations (EFPIA), Chairman of the Innovation Board Sponsored Committee (EFPIA) and Deputy Chair of the Innovative Medicines Initiative (IMI) Governing Board.

Jean-Christophe Tellier is an experienced global leader. He was trained as a Medical Doctor and specialized in rheumatology. He has built a distinguished 25-year career in the biopharmaceutical industry, taking on different global leadership responsibilities in different parts of the world.

His patient-centric approach, his passion for science, combined with his strategic and operational skills, have allowed him to significantly contribute to UCB's success in recent years.

For Jean-Christophe "engaging the patient in our vision is the best way for our company to be successful in the long term. Having a holistic view of a patient, of his/her life in his/her environment is essential to ensure effective treatment". Jean-Christophe also believes that "all healthcare players - physicians, payors, carers, industry and academia - should cooperate even more effectively and become stronger partners sharing a same goal: improving patient care".

As a leader, Jean-Christophe has always had a passion for developing people, which he sees as "a key force to drive company success". His ambition is to continue to further engage UCB teams behind the company's vision and fully leverage UCB's strong culture and talents.

Key positions

Prior to UCB, Jean-Christophe held the following positions:

2009	Ipsen: President and General Manager of Ipsen's North American operations
2008	Macrogenics: Maryland-based public biotechnology company Executive Vice President and Chief Commercial Officer
1989 – 2008	Novartis: CEO of Novartis Pharma France CEO of Novartis Pharma Belgium – was President of the Board of the Belgian Pharma Trade association (pharma.be) Built his career in several local and global marketing and sales positions; was a.o. Head of Novartis' Global Business Franchise in Arthritis, Bone and Muscle Disease

Education

Doctor of Medicine (M.D.) – University of Reims Champagne-Ardenne, France
Post-graduate: Rheumatologist - University of Paris V, France
Executive business programs at Harvard and INSEAD

Update: November 2017